Featured

Featured Videos

Julianna LeMieux, PhD, GEN’s Deputy Editor-in-Chief took a minute away from the talks, posters, and expo hall to join Uduak Thomas, Senior Editor at GEN, who is also in Denver, to talk about the meeting, the sessions they attended, and the trends that they are noticing. Some of the highlights were an interview with Jacob Thaysen, Illumina’s new CEO, a single cell initiative, how proteomics is trying to change Alzheimer’s detection, and the launch of PacBio’s new instrument—the Vega—complete with a review of the OneRepublic concert.

Genomics in Snowy Denver: A Video Update from ASHG

John SterlingGEN’s Editor-in-Chief, has been attending BPI since its inception, 20 years ago! Here, he took a minute away from the talks and posters to join Julianna LeMieux, PhD, Deputy Editor-in-Chief—who was at BPI for her second time—to talk about the first day of the meeting, the sessions they attended, and the trends that they are noticing. John also reflects on 20 years in the industry.

Bioprocessing in Boston: GEN Reports Live from BPI 2024

The State of Cell and Gene Therapy 2025

For this The State of Cell and Gene Therapy summit GEN has gathered a fantastic group of presenters from academia and industry to discuss the latest clinical advances and trends. Our speakers will discuss progress and challenges around new technologies, delivery vehicles, and clinical applications.
January 2025 cover

In the January issue of GEN we were honored to have Peter Hotez, MD, PhD, contribute to the first issue of the year with his essay, “Personal Reflections on Five Years of COVID-19.” Peter has been a leading voice on the importance of vaccination and has worked tirelessly to debunk false information concerning science and society. Rather than looking back, many of our stories in this issue look ahead at the year to come. We asked multiple experts to predict trends in the areas of NGS, multiomics, organoids, and more. In addition, Alex Philippidis, GEN’s senior business editor, kicked off the year with his Top 25 Biotech Companies Heading Into 2025.